Before administering cefazolin (Ancef), the nurse checks for a previous allergic reaction to:

A. Substance that can inhibit the growth of bacteria:

This definition is incorrect. The term "virulence" does not refer to a substance that inhibits bacterial growth. Instead, it pertains to the ability of a microorganism to cause disease.

B. Permanent, inheritable changes to DNA:

This definition is incorrect. Permanent, inheritable changes to DNA are typically referred to as mutations. While mutations can impact the characteristics of microorganisms, the term "virulence" specifically relates to disease-causing ability rather than genetic changes.

C. When a microbe is no longer affected by a drug following treatment with anti-infectives:

This definition is incorrect. The phenomenon described here is known as drug resistance or antimicrobial resistance. It refers to the ability of microorganisms to survive and multiply in the presence of antimicrobial agents, rendering the drugs ineffective.

D. The severity of disease that an organism is able to cause:

This definition is correct. Virulence refers to the degree or severity of disease that an organism, such as a bacterium or virus, is capable of causing. Microorganisms with high virulence can cause severe illness or death in infected hosts, while those with low virulence may cause milder symptoms or no symptoms at all.

1. Do not have to demonstrate effectiveness:

This statement is generally true under DSHEA regulations. Unlike pharmaceutical drugs, dietary supplements are not required to undergo rigorous testing to demonstrate their effectiveness in treating, preventing, or curing specific health conditions before they are marketed. However, manufacturers are prohibited from making unsubstantiated claims about the effectiveness of their products.

B. Are determined to be safe before being placed on the market:

Under DSHEA regulations, dietary supplement manufacturers are responsible for ensuring the safety of their products before they are marketed. However, unlike pharmaceutical drugs, dietary supplements do not undergo premarket approval by the Food and Drug Administration (FDA) to verify their safety and efficacy. Instead, manufacturers are required to notify the FDA of their intent to market a new dietary ingredient (NDI) and provide evidence of the ingredient’s safety.

C. Are checked for label accuracy:

The FDA regulates dietary supplements to ensure that their labels are accurate and truthful. However, the extent of label accuracy checking varies, and the FDA does not routinely test every dietary supplement product on the market. Instead, the FDA relies on postmarket surveillance, consumer complaints, and other mechanisms to identify and address inaccuracies or violations of labeling regulations.

D. Are tested prior to marketing:

Unlike pharmaceutical drugs, dietary supplements are not required to undergo premarket testing to demonstrate their safety or efficacy before they are marketed. While manufacturers are responsible for ensuring the safety of their products, there is no formal premarket testing requirement under DSHEA regulations.